MXPA05006272A - Novedosos antagonistas de receptores de mch. - Google Patents

Novedosos antagonistas de receptores de mch.

Info

Publication number
MXPA05006272A
MXPA05006272A MXPA05006272A MXPA05006272A MXPA05006272A MX PA05006272 A MXPA05006272 A MX PA05006272A MX PA05006272 A MXPA05006272 A MX PA05006272A MX PA05006272 A MXPA05006272 A MX PA05006272A MX PA05006272 A MXPA05006272 A MX PA05006272A
Authority
MX
Mexico
Prior art keywords
carboxylic acid
biphenyl
phenoxy
ethylsulfanylmethyl
amide
Prior art date
Application number
MXPA05006272A
Other languages
English (en)
Spanish (es)
Inventor
Michael Morin Junior John
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MXPA05006272A publication Critical patent/MXPA05006272A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MXPA05006272A 2002-12-11 2003-12-03 Novedosos antagonistas de receptores de mch. MXPA05006272A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43270102P 2002-12-11 2002-12-11
PCT/US2003/037071 WO2004052848A1 (en) 2002-12-11 2003-12-03 Novel mch receptor antagonists

Publications (1)

Publication Number Publication Date
MXPA05006272A true MXPA05006272A (es) 2005-08-19

Family

ID=32507985

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05006272A MXPA05006272A (es) 2002-12-11 2003-12-03 Novedosos antagonistas de receptores de mch.

Country Status (9)

Country Link
US (1) US7132456B2 (enExample)
EP (1) EP1572637A1 (enExample)
JP (1) JP2006509801A (enExample)
CN (1) CN1726189A (enExample)
AU (1) AU2003302925A1 (enExample)
BR (1) BR0316948A (enExample)
CA (1) CA2509042A1 (enExample)
MX (1) MXPA05006272A (enExample)
WO (1) WO2004052848A1 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7329656B2 (en) 2004-10-08 2008-02-12 H. Lundbeck A/S Arylthiobenzylpiperidine derivatives
US7446204B2 (en) 2004-10-08 2008-11-04 H. Lundbeck A/S Amino substituted aryloxybenzylpiperidine derivatives
ATE446962T1 (de) 2004-12-17 2009-11-15 Lilly Co Eli Thiazolopyridinon-derivate als mch- rezeptorantagonisten
CN101184732B (zh) * 2005-03-28 2012-05-16 株式会社半导体能源研究所 蒽衍生物、发光元件用材料、发光元件、发光装置和电子器件
US7731377B2 (en) * 2006-03-21 2010-06-08 Semiconductor Energy Laboratory Co., Ltd. Backlight device and display device
US7772162B2 (en) 2006-03-27 2010-08-10 Board Of Regents, The University Of Texas System Use of fluorocarbon surfactants to improve the productivity of gas and gas condensate wells
US20070225176A1 (en) * 2006-03-27 2007-09-27 Pope Gary A Use of fluorocarbon surfactants to improve the productivity of gas and gas condensate wells
PT2402319T (pt) * 2006-03-31 2017-12-11 Novartis Ag Inibidores de dgat
US8633175B2 (en) 2006-08-09 2014-01-21 Glaxosmithkline Llc Compounds as antagonists or inverse agonists at opioid receptors
WO2008026614A1 (en) * 2006-08-30 2008-03-06 Semiconductor Energy Laboratory Co., Ltd. Method for synthesizing anthracene derivative and anthracene derivative, light emitting element, light emitting device, electronic device
US7723722B2 (en) 2007-03-23 2010-05-25 Semiconductor Energy Laboratory Co., Ltd. Organic compound, anthracene derivative, and light-emitting element, light-emitting device, and electronic device using anthracene derivative
RU2009138310A (ru) * 2007-03-23 2011-04-27 Борд Оф Риджентс, Зе Юниверсити Оф Техас Систем (Us) Способ обработки формации растворителем
US8403050B2 (en) * 2007-03-23 2013-03-26 3M Innovative Properties Company Method for treating a hydrocarbon-bearing formation with a fluid followed by a nonionic fluorinated polymeric surfactant
US20080286445A1 (en) * 2007-05-17 2008-11-20 Semiconductor Energy Laboratory Co., Ltd. Composition, and method of fabricating light-emitting element
AR066169A1 (es) * 2007-09-28 2009-07-29 Novartis Ag Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat
EP2238312A4 (en) * 2007-11-30 2011-08-17 Univ Texas METHOD FOR IMPROVING THE PRODUCTIVITY OF OIL EXTRACTION OILS
WO2010005066A1 (en) * 2008-07-08 2010-01-14 Semiconductor Energy Laboratory Co., Ltd. Carbazole derivative, light-emitting element material, light-emitting element, and light-emitting device
EP2166001B1 (en) * 2008-09-19 2011-07-20 Semiconductor Energy Laboratory Co., Ltd. Carbazole Derivative and Method for Producing the Same
US8410284B2 (en) 2008-10-22 2013-04-02 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
WO2010051206A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
JP2013520502A (ja) 2010-02-25 2013-06-06 メルク・シャープ・エンド・ドーム・コーポレイション 有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体
CA2826649C (en) 2011-02-25 2016-07-26 Merck Sharp & Dohme Corp. Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
US20140045746A1 (en) 2012-08-02 2014-02-13 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
JP2016516004A (ja) 2013-02-22 2016-06-02 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. 抗糖尿病二環式化合物
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
KR102844041B1 (ko) 2016-02-26 2025-08-11 가부시키가이샤 한도오따이 에네루기 켄큐쇼 유기 화합물, 발광 소자, 발광 장치, 전자 기기, 및 조명 장치
WO2018106518A1 (en) 2016-12-06 2018-06-14 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
WO2018118670A1 (en) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
BR102018007822A2 (pt) 2017-04-20 2018-11-06 Gilead Sciences, Inc. composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição
WO2019160882A1 (en) 2018-02-13 2019-08-22 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
KR102591947B1 (ko) 2018-04-19 2023-10-25 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
PE20210642A1 (es) 2018-07-13 2021-03-23 Gilead Sciences Inc Inhibidores de pd-1/pd-l1
US11236085B2 (en) 2018-10-24 2022-02-01 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
KR20260094346A (ko) 2023-11-09 2026-06-22 셰브론 필립스 케미컬 컴퍼니 엘피 크로뮴 촉매 활성화를 위한 시스템 및 방법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3535330A (en) * 1968-04-29 1970-10-20 Sandoz Ag 2,6-diphenyl - 4 - (p-(dilower-alkyl amino lower - alkoxy)phenyl)pyridines and derivatives thereof
US3928449A (en) * 1969-04-03 1975-12-23 Sandoz Ag Aminoalkoxy-terphenyls and the salts thereof
LU78484A1 (de) * 1977-11-10 1979-06-13 Ciba Geigy Ag Verfahren zur herstellung von benzoxazolyl-phenyl-stilbenen
DE2752361A1 (de) 1977-11-24 1979-06-07 Troponwerke Gmbh & Co Kg Neue indolderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
US7115750B1 (en) 1999-09-20 2006-10-03 Takeda Pharmaceutical Company Limited Melanin concentrating hormone antagonist

Also Published As

Publication number Publication date
CA2509042A1 (en) 2004-06-24
WO2004052848A1 (en) 2004-06-24
EP1572637A1 (en) 2005-09-14
CN1726189A (zh) 2006-01-25
US7132456B2 (en) 2006-11-07
BR0316948A (pt) 2005-10-18
US20060052449A1 (en) 2006-03-09
AU2003302925A1 (en) 2004-06-30
JP2006509801A (ja) 2006-03-23

Similar Documents

Publication Publication Date Title
WO2004052848A1 (en) Novel mch receptor antagonists
KR20170048588A (ko) 바이사이클릭 화합물
RU2673245C2 (ru) Производные 4-аминометилбензойной кислоты
JPWO2003029199A1 (ja) ベンゼン誘導体、その製造法および用途
PT2208727E (pt) Éteres diarílicos como antagonista do receptor opióide
TWI400071B (zh) 經取代之2-〔2-(苯基)乙胺〕烷醯胺衍生物
CA2415331A1 (en) Beta3 adrenergic agonists
AU2014244482B2 (en) Bicyclo [2.2.2] acid GPR120 modulators
US20120022116A1 (en) Compositions and methods for the treatment of pathological condition(s) related to gpr35 and/or gpr35-herg complex
EP1497260A1 (en) Novel methoxybenzamide compounds for use in mch receptor related disorders
EP3319444A1 (en) Mu opioid receptor modulators
CA2542220A1 (en) Novel mch receptor antagonists
NZ523951A (en) Phenoxybenzylamine derivatives as selective serotonin re-uptake inhibitors
BRPI0610119A2 (pt) compostos, uso dos compostos, composição farmacêutica, método de tratamento de uma doença, e, agente para a prevenção ou tratamento de uma doença
MXPA02005742A (es) 1,2-diaril bencimidazoles para el tratamiento de enfermedades asociadas con la activacion de la micrologia.
ES2939730T3 (es) Compuestos de heteroarilo de 5 miembros que contienen un resto hidroxamato y su uso
JP2006522012A (ja) ベンゾキサゾシンおよびそのモノアミン再吸収阻害剤としての用途
BRPI0610240A2 (pt) compostos, composição farmacêutica, uso do composto, método de tratamento de uma doença, e, processo para preparação de um composto
AU561190B2 (en) Aromatic amines
WO2005100301A1 (en) 2-aryloxyethyl glycine derivatives and their use as glycine transport inhibitors
Yamamoto et al. Identification of 1-Methyl-N-(propan-2-yl)-N-({2-[4-(trifluoromethoxy) phenyl] pyridin-4-yl} methyl)-1H-imidazole-4-carboxamide as a Potent and Orally Available Glycine Transporter 1 Inhibitor
WO2007036730A9 (en) Thiophene derivatives as ppar agonists i
KR19990038717A (ko) 3-(치환-페닐티오)-4-하이드록시퀴놀린-2(1h)-온 유도체 및 그들의 제조방법
JP2004339061A (ja) ベンゼン誘導体、その製造法および用途
MX2007014266A (es) Nuevos derivados de cromano o tetrahidronaftaleno 8-sulfonil-3-aminosustituidos que modulan al receptor de 5-hidroxi-triptamina 6.